Effect of estrogen on ventricular repolarization in menopausal patients with syndrome X and effects of nicorandil.
Syndrome X may exhibit myocardial ischemia and is associated with estrogen deficiency. We sought to assess the possible role of estrogen in modulating the characteristics of ventricular repolarization by measurement of QT interval and QT dispersion in patients with syndrome X. We prospectively used 12-lead electrocardiograms and echocardiograms to study 52 consecutive menopausal patients with syndrome X (group subdivided into subgroup 1a, 32 patients who received nicorandil, an adenosine triphosphate-sensitive potassium ion channel opener; subgroup 1b, 20 patients without dosing nicorandil). For comparisons, a control group consisted of age-matched and echocardiographic left ventricular mass index-matched 20 healthy menopausal women. Baseline QT intervals and QT dispersion were similar between the 2 groups (subgroup 1a and controls). After administration of estrogen, there was significant prolongation of maximal QTc intervals and reduction in QT or QTc dispersion compared with baseline in patients with syndrome X. The changes returned to baseline after nicorandil administration. Control subjects had no changes with administration of estrogen. Thus, estrogen modulates characteristics of ventricular repolarization, which appears to be mediated by blocking adenosine triphosphate-sensitive potassium ion channel. The effects of estrogen on QT intervals may be different between menopausal women with or without syndrome X.
Lee
T M
TM
College of Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei.
Su
S F
SF
Lee
Y T
YT
Tsai
C H
CH
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D016022:Case-Control Studies; D004562:Electrocardiography / Q000187:drug effects; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008593:Menopause / Q000502:physiology*; D017566:Microvascular Angina / Q000503:physiopathology*; D008875:Middle Aged; D020108:Nicorandil / Q000494:pharmacology*; D015221:Potassium Channels / Q000187:drug effects; D011446:Prospective Studies
D000889:Anti-Arrhythmia Agents; D004966:Estrogens, Conjugated (USP); D015221:Potassium Channels; D020108:Nicorandil